📊 SANA Key Takeaways
Is Sana Biotechnology, Inc. (SANA) a Good Investment?
Sana is a pre-commercial biotech company with no revenue and unsustainable cash burn of $144.8M annually against only $71.9M in cash reserves, implying sub-6-month runway. While the debt-free balance sheet and improving loss trajectory (EPS improved 17.2% YoY) are positive, fundamental financial health is severely compromised by lack of commercialization and operational sustainability.
Why Buy Sana Biotechnology, Inc. Stock? SANA Key Strengths
- Zero long-term debt provides financial flexibility and reduces solvency risk
- Improving loss trend with 17.2% YoY EPS improvement suggests operational discipline
- Healthy liquidity ratios (1.89x current and quick) with reasonable asset base of $416.9M
SANA Stock Risks: Sana Biotechnology, Inc. Investment Risks
- Pre-commercial with zero revenue; company is entirely dependent on capital markets for survival
- Unsustainable cash burn of $144.8M annually with only $71.9M cash; critical funding urgency within months
- Negative returns on equity (-151.8%) and assets (-58.6%) indicate significant shareholder value destruction
Key Metrics to Watch
- Cash runway and financing activities (Form 8-K, prospectus filings)
- Operating cash burn rate trends and operating loss reduction pace
- Clinical trial milestones, regulatory submissions, and partnership announcements
Sana Biotechnology, Inc. (SANA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Sana Biotechnology, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
SANA Profit Margin, ROE & Profitability Analysis
SANA vs Healthcare Sector: How Sana Biotechnology, Inc. Compares
How Sana Biotechnology, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Sana Biotechnology, Inc. Stock Overvalued? SANA Valuation Analysis 2026
Based on fundamental analysis, Sana Biotechnology, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Sana Biotechnology, Inc. Balance Sheet: SANA Debt, Cash & Liquidity
SANA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Sana Biotechnology, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.46 indicates the company is currently unprofitable.
SANA Revenue Growth, EPS Growth & YoY Performance
Sana Biotechnology, Inc. Dividends, Buybacks & Capital Allocation
SANA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Sana Biotechnology, Inc. (CIK: 0001770121)
📋 Recent SEC Filings
❓ Frequently Asked Questions about SANA
What is the AI rating for SANA?
Sana Biotechnology, Inc. (SANA) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are SANA's key strengths?
Claude: Zero long-term debt provides financial flexibility and reduces solvency risk. Improving loss trend with 17.2% YoY EPS improvement suggests operational discipline.
What are the risks of investing in SANA?
Claude: Pre-commercial with zero revenue; company is entirely dependent on capital markets for survival. Unsustainable cash burn of $144.8M annually with only $71.9M cash; critical funding urgency within months.
What is SANA's revenue and growth?
Sana Biotechnology, Inc. reported revenue of N/A.
Does SANA pay dividends?
Sana Biotechnology, Inc. does not currently pay dividends.
Where can I find SANA SEC filings?
Official SEC filings for Sana Biotechnology, Inc. (CIK: 0001770121) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is SANA's EPS?
Sana Biotechnology, Inc. has a diluted EPS of $-0.96.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is SANA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Sana Biotechnology, Inc. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is SANA stock overvalued or undervalued?
Valuation metrics for SANA: ROE of -151.8% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy SANA stock in 2026?
Our dual AI analysis gives Sana Biotechnology, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is SANA's free cash flow?
Sana Biotechnology, Inc.'s operating cash flow is $-143.8M, with capital expenditures of $938.0K.
How does SANA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -151.8% (avg: 15%), current ratio 1.89 (avg: 2).